Assessing Platelet Refractoriness And The Appropriate Use

Ryan Thomas, MD Sarah Barnhard, MD. Platelet transfusions have become a mainstay of treatment that are invaluable in the management of patients with hematologic and oncologic disorders, significantly reducing the incidence of hemorrhagic complications in these patients. 1,2 It has been shown that 25% to 70% of patients with hematologic disease and cancer experience at least one inadequate

Actived: Tuesday Jan 14, 2020


Related topics